HIMS Equity Alert: Kessler Topaz Meltzer & Check, LLP Alerts Shareholders of Securities Fraud Class Action Lawsuit Filed against Hims & Hers Health, Inc. (HIMS)
CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:
If you suffered Hims & Hers losses, you may CLICK HERE or copy and paste the following link into your browser: https://www.ktmc.com/new-cases/hims-hers-health-inc?utm_source=NewsFile&utm_medium=PR
You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected].
DEFENDANTS' ALLEGED MISCONDUCT:
The complaints allege that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Hims & Hers was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk;" (2) as a result, there was a substantial risk that Hims & Hers' collaboration with Novo Nordisk would be terminated; and (3) that, as a result of the foregoing, Defendants' positive statements about the company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
[ This video cannot be displayed. Please visit the source: https://www.youtube.com/v/xuStgUOFgE8 ]
Please CLICK HERE to view our video or copy and paste this link into your browser: https://youtu.be/xuStgUOFgE8
THE LEAD PLAINTIFF PROCESS:
Hims & Hers investors may, no later than August 25, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
Kessler Topaz Meltzer & Check, LLP encourages Hims & Hers investors who have suffered significant losses to contact the firm directly to acquire more information.
CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: https://www.ktmc.com/new-cases/hims-hers-health-inc?utm_source=NewsFile&utm_medium=PR
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP:
Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.
CONTACT:
Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
[email protected]
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/259360
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
24 minutes ago
- New York Times
India and Trump Still Don't Have a Tariff Deal: Here's Why That Matters
India was eager to start negotiating with President Trump over tariffs. Prime Minister Narendra Modi visited Washington right after the inauguration. Hopes were high for a quick trade agreement with a re-elected president who prizes deals. Six months later, there is still no deal. With tariffs threatened and deadlines blown, India and the United States are up against a wall. On Friday, the United States is ready to impose a 26 percent tariff on all goods it imports from India. Dozens of countries are facing the same imperative. But India, a democracy and the world's most populous country, is a major commercial partner of the United States. Total trade between the two countries was roughly $130 billion last year. The nations have deep cultural and demographic ties. Indian immigrants and Americans with Indian roots occupy a stratum of leadership roles in U.S. business, academia and politics. Their economic ties are of vital and growing importance, to India especially. And for 25 years, Washington has been courting India as a military partner, sometimes explicitly as a counterweight to China. Indian officials have been shuttling back and forth from New Delhi to Washington for months. On Thursday, India's commerce minister, Piyush Goyal, told the Reuters news agency that the negotiators were 'making fantastic progress.' There is the real prospect of talks going beyond this week. The Indian government has invited Mr. Trump to India for a defense summit in the fall, when Mr. Goyal has said he believes a bigger deal could be struck. Want all of The Times? Subscribe.
Yahoo
30 minutes ago
- Yahoo
TD Cowen Sees Upside for Thermo Fisher (TMO) With Modest Q2 Growth
Thermo Fisher Scientific Inc. (NYSE:TMO) ranks among the . On July 16, TD Cowen maintained its Buy rating on Thermo Fisher Scientific Inc. (NYSE:TMO) but reduced its price target from $570 to $550. Citing current low levels and market mood, the firm believes an in-line second quarter will be enough to lift TMO shares. According to TD Cowen, biopharma activity was typical in the second quarter and was untouched by tariff or MFN issues, which the firm considers to be encouraging news. With expectations for 'similar' organic growth to the first quarter, the firm reduced its second-quarter organic growth estimate from 1.2% to 1.0%, which was lower than the analysts' consensus of 0.7%. One of the top biotech and life sciences companies in the United States, Thermo Fisher Scientific Inc. (NYSE:TMO) offers a broad range of products and services. The company has grown significantly since its founding, mostly as a result of a number of well-timed acquisitions, such as those of Affymetrix and Life Technologies. While we acknowledge the potential of TMO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Exelixis Inc (EXEL) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Challenges
Total Revenue: Approximately $568 million for Q2 2025. Cabozantinib Franchise Net Product Revenue: $520 million, with CABOMETYX net product revenues at $518 million. Gross-to-Net Cabozantinib Franchise: 30.2% for Q2 2025. Collaboration Revenues: Approximately $48.2 million, including $43.4 million in royalties from partners Ipsen and Takeda. Total Operating Expenses: $355 million for Q2 2025. GAAP Net Income: Approximately $184.8 million or $0.68 per share basic and $0.65 per share diluted. Non-GAAP Net Income: Approximately $212.6 million or $0.78 per share basic and $0.75 per share diluted. Cash and Marketable Securities: Approximately $1.4 billion as of June 30, 2025. Share Repurchase: Approximately $302 million worth of shares repurchased, retiring approximately 7.5 million shares at an average price of $40.10 per share. Warning! GuruFocus has detected 5 Warning Sign with EXEL. Release Date: July 28, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Exelixis Inc (NASDAQ:EXEL) reported strong second-quarter 2025 financial results with total revenues of approximately $568 million, driven by the cabozantinib franchise. The cabozantinib US business showed robust growth, with revenues increasing 19% year over year to $520 million. The launch of CABOMETYX in neuroendocrine tumors (NETs) is off to a strong start, quickly capturing a 35% new patient share in the oral therapies segment. Positive topline results from the STELLAR-303 trial in colorectal cancer, demonstrating a statistically significant improvement in overall survival. Exelixis Inc (NASDAQ:EXEL) maintains a strong balance sheet with approximately $1.4 billion in cash and marketable securities, allowing for continued R&D investment and share repurchases. Negative Points The decision not to advance the STELLAR-305 trial in head and neck cancer into Phase 3 due to competitive landscape and commercial opportunity concerns. Higher gross-to-net deductions in the second quarter of 2025, primarily related to increased 340B volume, impacting overall profitability. Clinical trial sales were significantly lower in the second quarter compared to the first quarter of 2025, indicating potential volatility in this revenue stream. The competitive landscape in oncology remains challenging, with Exelixis Inc (NASDAQ:EXEL) needing to make tough capital allocation decisions. The regulatory environment is described as highly dynamic, necessitating a conservative approach to data interpretation and communication. Q & A Highlights Q: Can you provide any takeaways from the head and neck study that might be applicable to future studies? A: Amy Peterson, Chief Medical Officer, stated that while they are not sharing data at this time, zanzalintinib is a franchise molecule with much more to be done beyond the initial six pivotal trials. Rigorous drug development requires continuous assessment of emerging data. Q: How sustainable are the market share gains for CABOMETYX, and can you achieve similar market share in neuroendocrine tumors (NET) as in renal cell carcinoma (RCC)? A: Michael Morrissey, CEO, expressed confidence in sustaining market share gains, noting a strong franchise with CABOMETYX in RCC. Patrick Haley, EVP of Commercial, added that the NET launch is off to a strong start with a 35% market share in the second-line-plus oral market, and they expect continued growth. Q: How do you see zanzalintinib positioned in the colorectal cancer landscape, especially with new treatment options emerging? A: Amy Peterson highlighted the significance of the STELLAR-303 trial's positive overall survival results in colorectal cancer, emphasizing it as the first IO TKI combination to show a statistically significant survival benefit. They plan to discuss these results with regulators and share them at a medical conference. Q: Can you comment on the pricing dynamics for cabozantinib, especially with respect to 340B volume and reimbursement? A: Christopher Senner, CFO, noted an increase in 340B volume, which is a highly discounted segment, impacting gross-to-net calculations. They are projecting gross-to-net closer to 30% due to this shift. Q: Regarding STELLAR-303, how important is it to demonstrate a benefit in patients with liver metastases? A: Amy Peterson stated that while they have a positive overall survival readout in the intent-to-treat population, they continue to follow the non-liver metastases subgroup. They look forward to sharing all data once available. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
